Empyrean Capital Partners Portfolio holdings
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AbbVie
ABBV
|
+$58.6M |
| 2 |
NIHD
NII Holdings, Inc. Common Stock
NIHD
|
+$43.8M |
| 3 |
Pfizer
PFE
|
+$21.1M |
| 4 |
SRG
Seritage Growth Properties
SRG
|
+$19.8M |
| 5 |
Comcast
CMCSA
|
+$19.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
DTV
DIRECTV COM STK (DE)
DTV
|
+$149M |
| 2 |
RAI
Reynolds American Inc
RAI
|
+$111M |
| 3 |
AGN
Allergan plc
AGN
|
+$103M |
| 4 |
BRCM
BROADCOM CORP CL-A
BRCM
|
+$91.9M |
| 5 |
YHOO
Yahoo Inc
YHOO
|
+$66.8M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Communication Services | 10.23% |
| 2 | Financials | 9.07% |
| 3 | Healthcare | 8.27% |
| 4 | Technology | 6.97% |
| 5 | Industrials | 5.36% |
Similar funds
Empyrean Capital Partners's Q3 2015 Portfolio in Review
As of Q3 2015, Empyrean Capital Partners held 76 positions worth $2.03B, down 5.1% from $2.14B the previous quarter. Its ten largest holdings account for 55% of the portfolio.
Empyrean Capital Partners withdrew a net $127M in Q3 2015, closing 23 positions and reducing 13 holdings. Its most notable exit was DIRECTV COM STK (DE), an estimated $149M position sold in full.
By sector, the portfolio is most concentrated in Communication Services at 10% of assets, up from 8.8% a quarter earlier, followed by Financials and Healthcare.
Against the trend, Empyrean Capital Partners opened a new position in AbbVie worth $49M.
- Empyrean Capital Partners's largest Q3 2015 buy was AbbVie: 900,000 shares worth $49M.
- Empyrean Capital Partners added most to Pfizer in Q3 2015, an estimated $21.1M increase.
- Empyrean Capital Partners's biggest Q3 2015 reduction was Allergan plc, cutting an estimated $103M.
- Empyrean Capital Partners fully exited DIRECTV COM STK (DE) in Q3 2015, selling an estimated $149M.
- Empyrean Capital Partners's ten largest holdings make up 55% of its $2.03B portfolio in Q3 2015.
- Empyrean Capital Partners opened 17 new positions and closed 23 in Q3 2015.
- Empyrean Capital Partners's portfolio value fell 5.1% quarter-over-quarter to $2.03B.
Based on Empyrean Capital Partners's 13F filing for Q3 2015, filed 16 Nov 2015.